Rising Cannabis Legalization And Wellness Trends Will Fuel Expansion

AnalystHighTarget

Not Invested

Consensus Narrative from 7 Analysts

Published

10 Aug 25

Updated

21 Aug 25

AnalystHighTarget's Fair Value

CA$3.12

40.7% undervalued

21 Aug

CA$1.85

-21.6%

17.8%

-21.6%

17.8%

Author's Valuation

CA$3.1

40.7% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

CA$3.1

40.7% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

1.26%

Pharma revenue growth rate

0.58%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.61%

Calculation

US$6.59m

Earnings '28

157.53x

PE Ratio '28

US$1.04b

Market Cap '28

US$1.04b

Market Cap '28

380.14m

No. shares '28

US$2.73

Share Price '28

US$2.73 Share Price '28

Discounted to 2025 @ 6.71% p.a.

US$2.25

Fair Value '25

US$2.25 Fair Value '25

Converted to CAD @ 1.3877 USD/CAD Exchange Rate

CA$3.12

Fair Value '25